• Julia Mayerle on the validation of plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma
    2025/06/19

    Can a multi-metabolite blood test improve early pancreatic cancer detection? We spoke to Julia Mayerle about the METAPAC study, which sought to validate the ability of plasma metabolic signatures to find resectable tumors and reduce unnecessary invasive procedures in high-risk patients.

    Read the full article:

    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00056-1/fulltext?dgcid=buzzsprout_icw_podcast_June_25_langas

    Continue this conversation on social!

    Follow us today at...

    https://bsky.app/profile/lancetgastrohep.bsky.social

    https://www.linkedin.com/company/langastro/

    https://instagram.com/thelancetgroup

    https://facebook.com/thelancetmedicaljournal

    https://youtube.com/thelancettv

    続きを読む 一部表示
    27 分
  • Salvatore Piano on the global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis
    2025/04/09

    How does acute kidney injury presentation and management differ globally for patients hospitalised with cirrhosis?

    We spoke to Salvatore Piano, corresponding author of the landmark International Club of Ascites GLOBAL AKI study, about new data on regional variations in severity, phenotype, treatment, and outcomes across 5 continents.

    Read the full article:

    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00006-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas

    Continue this conversation on social!

    Follow us today at...

    https://bsky.app/profile/lancetgastrohep.bsky.social

    https://www.linkedin.com/company/langastro/

    https://instagram.com/thelancetgroup

    https://facebook.com/thelancetmedicaljournal

    https://youtube.com/thelancettv

    続きを読む 一部表示
    19 分
  • John Chia on the ASCOLT trial of adjuvant aspirin for colorectal cancer
    2025/03/06

    John Chia discusses the results of the ASCOLT trial, which explored the effect of aspirin after completion of standard adjuvant therapy for patients with colorectal cancer.

    Read the full article:

    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00387-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas

    Continue this conversation on social!

    Follow us today at...

    https://bsky.app/profile/lancetgastrohep.bsky.social

    https://www.linkedin.com/company/langastro/

    https://instagram.com/thelancetgroup

    https://facebook.com/thelancetmedicaljournal

    https://youtube.com/thelancettv

    続きを読む 一部表示
    13 分
  • Hannes Hagström on screening for advanced liver fibrosis alongside retina scanning in people with type 2 diabetes
    2025/01/10

    Hannes Hagström discusses a study investigating the feasibility of screening for advanced liver fibrosis alongside retina scanning in people with type 2 diabetes.

    Read the full article:
    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00313-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas

    Continue this conversation on social!

    Follow us today at...

    https://bsky.app/profile/lancetgastrohep.bsky.social

    https://www.linkedin.com/company/langastro/

    https://instagram.com/thelancetgroup

    https://facebook.com/thelancetmedicaljournal

    https://youtube.com/thelancettv

    続きを読む 一部表示
    21 分
  • Cathy Lu on intestinal ultrasound for assessing and monitoring Crohn's disease small bowel strictures
    2024/12/12

    Cathy Lu (University of Calgary) discusses a consensus statement on the use of intestinal ultrasound for assessing and monitoring small bowel strictures in Crohn's disease.

    Read the full article:
    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00265-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas

    Continue this conversation on social!

    Follow us today at...

    https://bsky.app/profile/lancetgastrohep.bsky.social

    https://www.linkedin.com/company/langastro/

    https://instagram.com/thelancetgroup

    https://facebook.com/thelancetmedicaljournal

    https://youtube.com/thelancettv

    続きを読む 一部表示
    11 分
  • Peter De Cruz on the PREDICT-UC trial of intensified versus standard dose infliximab for steroid-refractory acute severe ulcerative colitis
    2024/11/06

    Peter De Cruz (University of Melbourne) discusses the PREDICT-UC trial of intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.

    Read the full article:
    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00200-0?dgcid=buzzsprout_icw_podcast_generic_langas

    Continue this conversation on social!

    Follow us today at...

    https://bsky.app/profile/lancetgastrohep.bsky.social

    https://www.linkedin.com/company/langastro/

    https://instagram.com/thelancetgroup

    https://facebook.com/thelancetmedicaljournal

    https://youtube.com/thelancettv

    続きを読む 一部表示
    15 分
  • Shahida Din and Beatriz Gros on the harms associated with receiving placebo in trials of drugs for inflammatory bowel disease
    2024/11/01

    Shahida Din (Western General Hospital, Edinburgh) and Beatriz Gros (Reina Sofía University Hospital, Cordoba) discuss two new papers on the harms associated with receiving placebo in induction and maintenance trials of biological therapies and small molecules in inflammatory bowel disease.

    Read the full articles:
    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00264-4/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas
    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00233-4/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas

    Continue this conversation on social!

    Follow us today at...

    https://bsky.app/profile/lancetgastrohep.bsky.social

    https://www.linkedin.com/company/langastro/

    https://instagram.com/thelancetgroup

    https://facebook.com/thelancetmedicaljournal

    https://youtube.com/thelancettv

    続きを読む 一部表示
    34 分
  • Arndt Vogel on the NALIRICC trial of nanoliposomal irinotecan in pretreated advanced biliary tract cancer
    2024/07/31

    Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.

    Read the full article:
    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00119-5?dgcid=buzzsprout_icw_podcast_generic_langas

    Continue this conversation on social!

    Follow us today at...

    https://bsky.app/profile/lancetgastrohep.bsky.social

    https://www.linkedin.com/company/langastro/

    https://instagram.com/thelancetgroup

    https://facebook.com/thelancetmedicaljournal

    https://youtube.com/thelancettv

    続きを読む 一部表示
    18 分